Vitamin D3 and deconvoluting a rash
Open Access
- 24 January 2023
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 8 (2)
Abstract
BACKGROUND: Adverse drug reactions are unpredictable immunologic events presenting frequent challenges to clinical management. Systemically administered cholecalciferol (vitamin D 3 ) has immunomodulatory properties. In this randomized, double-blinded, placebo-controlled interventional trial of healthy human adults, we investigated the clinical and molecular immunomodulatory effects of a single high dose of oral vitamin D 3 on an experimentally induced chemical rash. METHODS: Skin inflammation was induced with topical nitrogen mustard (NM) in 28 participants. Participant-specific inflammatory responses to NM alone were characterized using clinical measures, serum studies, and skin tissue analysis over the next week. All participants underwent repeat NM exposure to the opposite arm and then received placebo or 200,000 IU cholecalciferol intervention. The complete rash reaction was followed by multi-omic analysis, clinical measures, and serum studies over 6 weeks. RESULTS: Cholecalciferol mitigated acute inflammation in all participants and achieved 6 weeks of durable responses. Integrative analysis of skin and blood identified an unexpected divergence in response severity to NM, corroborated by systemic neutrophilia and significant histopathologic and clinical differences. Multi-omic and pathway analyses revealed a 3-biomarker signature (CCL20, CCL2, CXCL8) unique to exaggerated responders that is suppressed by cholecalciferol and implicates IL-17 signaling involvement. CONCLUSION: High-dose systemic cholecalciferol may be an effective treatment for severe reactions to topical chemotherapy. Our findings have broad implications for cholecalciferol as an antiinflammatory intervention against the development of exaggerated immune responses. TRIAL REGISTRATION: clinicaltrials.gov (NCT02968446). FUNDING: NIH and National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS; grants U01AR064144, U01AR071168, P30 AR075049, U54 AR079795, and P30 AR039750 (CWRU)).Keywords
Funding Information
- National Institutes of Health and National Institute of Arthritis and Musculoskeletal and Skin Diseases (U01AR064144-01,U01AR071168,U01AR075049)
This publication has 76 references indexed in Scilit:
- IL-17A Induces Pro-Inflammatory Cytokines Production in Macrophages via MAPKinases, NF-κB and AP-1Cellular Physiology and Biochemistry, 2013
- Topical Chemotherapy in Cutaneous T-cell LymphomaJAMA Dermatology, 2013
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- Inhalation of sulfur mustard causes long-term T cell-dependent inflammation: Possible role of Th17 cells in chronic lung pathologyInternational Immunopharmacology, 2012
- Phase I Clinical Trial of O6-Benzylguanine and Topical Carmustine in the Treatment of Cutaneous T-Cell Lymphoma, Mycosis Fungoides TypeArchives of Dermatology, 2012
- Th17 Cytokines Stimulate CCL20 Expression in Keratinocytes In Vitro and In Vivo: Implications for Psoriasis PathogenesisJournal of Investigative Dermatology, 2009
- ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networksBioinformatics, 2009
- Differential gene expression profiling of mouse skin after sulfur mustard exposure: Extended time response and inhibitor effectToxicology and Applied Pharmacology, 2009
- Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sitesJournal of Clinical Investigation, 2007
- Gene Expression Omnibus: NCBI gene expression and hybridization array data repositoryNucleic Acids Research, 2002